Regulatory Approvals

After a Decade Without a New Option, FDA Approves Amivantamab for Head and Neck Cancer

By

Regulatory Approvals — After a Decade Without a New Option, FDA Approves Amivantamab for Head and Neck Cancer  Oncodaily

Read the original at Regulatory Approvals ↗

Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. November 6, 2026.

By

Related Post

Regulatory Approvals

FDA clears AI-powered intravascular ultrasound imaging platform

Regulatory Approvals

FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC

Regulatory Approvals

FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC

Financial News For All

Business Economy Finance

Commodities Price Update: Crude Oil $90.71, Brent $97.85, Copper $6.27, Coal $104.75 — Nov 6, 2026 10:00 AM EST

Regulation

What freight brokers should know following U.S. Supreme Court carrier liability ruling

Regulation

Advancing Cooperative Federalism: EPA Awards Cooperative Agreement to the Association of State and Territorial Health Officials to Support States and Territories on Environmental Health

Regulation

Administrator Zeldin Completes 4-Day Swing Across Florida, Meeting with Ranchers, Scientists, Energy Producers, and Manufacturers